Profile data is unavailable for this security.
About the company
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
- Revenue in USD (TTM)161.42m
- Net income in USD-239.61m
- Incorporated1999
- Employees389.00
- LocationAgenus Inc3 Forbes RdLEXINGTON 02421-7305United StatesUSA
- Phone+1 (781) 674-4400
- Fax+1 (781) 674-4200
- Websitehttps://agenusbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Werewolf Therapeutics Inc | 16.22m | -41.58m | 119.50m | 46.00 | -- | 1.01 | -- | 7.37 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Annovis Bio Inc | 0.00 | -47.53m | 120.32m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Relmada Therapeutics Inc | 0.00 | -94.30m | 122.51m | 20.00 | -- | 1.70 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
CervoMed Inc | 9.49m | -593.84k | 122.57m | 8.00 | 7.52 | 17.17 | -- | 12.91 | 1.97 | 1.97 | 2.04 | 0.8648 | 0.719 | -- | -- | 1,186,515.00 | -4.50 | -53.67 | -5.49 | -58.89 | -- | -- | -6.26 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 122.84m | 20.00 | -- | 1.06 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
Immunic Inc | 0.00 | -97.92m | 124.31m | 77.00 | -- | 1.49 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
FibroGen Inc | 167.49m | -240.46m | 124.34m | 486.00 | -- | -- | -- | 0.7424 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Athira Pharma Inc | 0.00 | -116.19m | 126.48m | 65.00 | -- | 1.18 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Nuvectis Pharma Inc | 0.00 | -22.38m | 127.57m | 13.00 | -- | 9.10 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Agenus Inc | 161.42m | -239.61m | 128.73m | 389.00 | -- | -- | -- | 0.7975 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 131.18m | 127.00 | -- | 1.65 | -- | 26.24 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -45.44m | 131.38m | 32.00 | -- | 0.8365 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
aTyr Pharma Inc | 588.00k | -53.93m | 133.19m | 56.00 | -- | 1.56 | -- | 226.52 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 135.74m | 28.00 | -- | 3.19 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
PDS Biotechnology Corp | 0.00 | -43.89m | 138.10m | 25.00 | -- | 3.71 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 May 2024 | 2.15m | 10.24% |
Deep Track Capital LPas of 31 Mar 2024 | 1.58m | 7.55% |
Point72 Asset Management LPas of 31 Mar 2024 | 1.51m | 7.17% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.33m | 6.31% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 781.56k | 3.72% |
Geode Capital Management LLCas of 31 Mar 2024 | 404.98k | 1.93% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 372.62k | 1.77% |
Renaissance Technologies LLCas of 31 Mar 2024 | 270.79k | 1.29% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 163.99k | 0.78% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 158.03k | 0.75% |